RRM1 and RRM2 pharmacogenetics: Association with phenotypes in HapMap cell lines and acute myeloid leukemia patients

Xueyuan Cao, Amit K. Mitra, Stanley Pounds, Kristine R. Crews, Varsha Gandhi, William Plunkett, M. Eileen Dolan, Christine Hartford, Susana Raimondi, Dario Campana, James Downing, Jeffrey E. Rubnitz, Raul C. Ribeiro, Jatinder K. Lamba

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Ribonucleotide reductase catalyzes an essential step in the cellular production of deoxyribonucleotide triphosphates and has been associated with clinical outcome in cancer patients receiving nucleoside analog-based chemotherapy. Materials & methods: In the current study, we sequenced the genes RRM1 and RRM2 in genomic DNA from HapMap cell lines with European (Utah residents with northern and western European ancestry [CEU]; n = 90) or African (Yoruba people in Ibadan, Nigeria [YRI]; n = 90) ancestry. Results: We identified 44 genetic variants including eight coding SNPs in RRM1 and 15 SNPs including one coding SNP in RRM2. RRM1 and RRM2 mRNA expression levels were significantly correlated with each other in both CEU and YRI lymphoblast cell lines, and in leukemic blasts from acute myeloid leukemia (AML) patients (AML97, n = 89; AML02, n = 187). Additionally, RRM1 expression was higher among patient features indicative of a high relapse hazard. We evaluated SNPs within the RRM1 and RRM2 genes in the HapMap lymphoblast cell lines from CEU and YRI panels for association with expression and cytarabine chemosensitivity. SNPs of potential significance were further evaluated in AML patients. RRM1 SNPs rs1042919 (which occurs in linkage disequilbrium with multiple other SNPs) and promoter SNP rs1561876 were associated with intracellular 1-β-d-arabinofuranosyl-CTP levels, response after remission induction therapy, risk of relapse and overall survival in AML patients receiving cytarabine and cladribine. Conclusion: These results suggest that SNPs within ribonucleotide reductase might be helpful predictive markers of response to nucleoside analogs and should be further validated in larger cohorts. Original submitted 2 April 2013; Revision submitted 8 July 201.

Original languageEnglish (US)
Pages (from-to)1449-1466
Number of pages18
JournalPharmacogenomics
Volume14
Issue number12
DOIs
StatePublished - Sep 1 2013

Fingerprint

HapMap Project
Pharmacogenetics
Acute Myeloid Leukemia
Single Nucleotide Polymorphism
Phenotype
Cell Line
Ribonucleotide Reductases
Cytarabine
Nucleosides
Cladribine
Deoxyribonucleotides
Cytidine Triphosphate
Remission Induction
Recurrence
Nigeria
Genes
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Cao, X., Mitra, A. K., Pounds, S., Crews, K. R., Gandhi, V., Plunkett, W., ... Lamba, J. K. (2013). RRM1 and RRM2 pharmacogenetics: Association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics, 14(12), 1449-1466. https://doi.org/10.2217/pgs.13.131

RRM1 and RRM2 pharmacogenetics : Association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. / Cao, Xueyuan; Mitra, Amit K.; Pounds, Stanley; Crews, Kristine R.; Gandhi, Varsha; Plunkett, William; Dolan, M. Eileen; Hartford, Christine; Raimondi, Susana; Campana, Dario; Downing, James; Rubnitz, Jeffrey E.; Ribeiro, Raul C.; Lamba, Jatinder K.

In: Pharmacogenomics, Vol. 14, No. 12, 01.09.2013, p. 1449-1466.

Research output: Contribution to journalArticle

Cao, X, Mitra, AK, Pounds, S, Crews, KR, Gandhi, V, Plunkett, W, Dolan, ME, Hartford, C, Raimondi, S, Campana, D, Downing, J, Rubnitz, JE, Ribeiro, RC & Lamba, JK 2013, 'RRM1 and RRM2 pharmacogenetics: Association with phenotypes in HapMap cell lines and acute myeloid leukemia patients', Pharmacogenomics, vol. 14, no. 12, pp. 1449-1466. https://doi.org/10.2217/pgs.13.131
Cao, Xueyuan ; Mitra, Amit K. ; Pounds, Stanley ; Crews, Kristine R. ; Gandhi, Varsha ; Plunkett, William ; Dolan, M. Eileen ; Hartford, Christine ; Raimondi, Susana ; Campana, Dario ; Downing, James ; Rubnitz, Jeffrey E. ; Ribeiro, Raul C. ; Lamba, Jatinder K. / RRM1 and RRM2 pharmacogenetics : Association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. In: Pharmacogenomics. 2013 ; Vol. 14, No. 12. pp. 1449-1466.
@article{4998fd8a33454102b2aaeb0428ba6169,
title = "RRM1 and RRM2 pharmacogenetics: Association with phenotypes in HapMap cell lines and acute myeloid leukemia patients",
abstract = "Background: Ribonucleotide reductase catalyzes an essential step in the cellular production of deoxyribonucleotide triphosphates and has been associated with clinical outcome in cancer patients receiving nucleoside analog-based chemotherapy. Materials & methods: In the current study, we sequenced the genes RRM1 and RRM2 in genomic DNA from HapMap cell lines with European (Utah residents with northern and western European ancestry [CEU]; n = 90) or African (Yoruba people in Ibadan, Nigeria [YRI]; n = 90) ancestry. Results: We identified 44 genetic variants including eight coding SNPs in RRM1 and 15 SNPs including one coding SNP in RRM2. RRM1 and RRM2 mRNA expression levels were significantly correlated with each other in both CEU and YRI lymphoblast cell lines, and in leukemic blasts from acute myeloid leukemia (AML) patients (AML97, n = 89; AML02, n = 187). Additionally, RRM1 expression was higher among patient features indicative of a high relapse hazard. We evaluated SNPs within the RRM1 and RRM2 genes in the HapMap lymphoblast cell lines from CEU and YRI panels for association with expression and cytarabine chemosensitivity. SNPs of potential significance were further evaluated in AML patients. RRM1 SNPs rs1042919 (which occurs in linkage disequilbrium with multiple other SNPs) and promoter SNP rs1561876 were associated with intracellular 1-β-d-arabinofuranosyl-CTP levels, response after remission induction therapy, risk of relapse and overall survival in AML patients receiving cytarabine and cladribine. Conclusion: These results suggest that SNPs within ribonucleotide reductase might be helpful predictive markers of response to nucleoside analogs and should be further validated in larger cohorts. Original submitted 2 April 2013; Revision submitted 8 July 201.",
author = "Xueyuan Cao and Mitra, {Amit K.} and Stanley Pounds and Crews, {Kristine R.} and Varsha Gandhi and William Plunkett and Dolan, {M. Eileen} and Christine Hartford and Susana Raimondi and Dario Campana and James Downing and Rubnitz, {Jeffrey E.} and Ribeiro, {Raul C.} and Lamba, {Jatinder K.}",
year = "2013",
month = "9",
day = "1",
doi = "10.2217/pgs.13.131",
language = "English (US)",
volume = "14",
pages = "1449--1466",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "12",

}

TY - JOUR

T1 - RRM1 and RRM2 pharmacogenetics

T2 - Association with phenotypes in HapMap cell lines and acute myeloid leukemia patients

AU - Cao, Xueyuan

AU - Mitra, Amit K.

AU - Pounds, Stanley

AU - Crews, Kristine R.

AU - Gandhi, Varsha

AU - Plunkett, William

AU - Dolan, M. Eileen

AU - Hartford, Christine

AU - Raimondi, Susana

AU - Campana, Dario

AU - Downing, James

AU - Rubnitz, Jeffrey E.

AU - Ribeiro, Raul C.

AU - Lamba, Jatinder K.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Background: Ribonucleotide reductase catalyzes an essential step in the cellular production of deoxyribonucleotide triphosphates and has been associated with clinical outcome in cancer patients receiving nucleoside analog-based chemotherapy. Materials & methods: In the current study, we sequenced the genes RRM1 and RRM2 in genomic DNA from HapMap cell lines with European (Utah residents with northern and western European ancestry [CEU]; n = 90) or African (Yoruba people in Ibadan, Nigeria [YRI]; n = 90) ancestry. Results: We identified 44 genetic variants including eight coding SNPs in RRM1 and 15 SNPs including one coding SNP in RRM2. RRM1 and RRM2 mRNA expression levels were significantly correlated with each other in both CEU and YRI lymphoblast cell lines, and in leukemic blasts from acute myeloid leukemia (AML) patients (AML97, n = 89; AML02, n = 187). Additionally, RRM1 expression was higher among patient features indicative of a high relapse hazard. We evaluated SNPs within the RRM1 and RRM2 genes in the HapMap lymphoblast cell lines from CEU and YRI panels for association with expression and cytarabine chemosensitivity. SNPs of potential significance were further evaluated in AML patients. RRM1 SNPs rs1042919 (which occurs in linkage disequilbrium with multiple other SNPs) and promoter SNP rs1561876 were associated with intracellular 1-β-d-arabinofuranosyl-CTP levels, response after remission induction therapy, risk of relapse and overall survival in AML patients receiving cytarabine and cladribine. Conclusion: These results suggest that SNPs within ribonucleotide reductase might be helpful predictive markers of response to nucleoside analogs and should be further validated in larger cohorts. Original submitted 2 April 2013; Revision submitted 8 July 201.

AB - Background: Ribonucleotide reductase catalyzes an essential step in the cellular production of deoxyribonucleotide triphosphates and has been associated with clinical outcome in cancer patients receiving nucleoside analog-based chemotherapy. Materials & methods: In the current study, we sequenced the genes RRM1 and RRM2 in genomic DNA from HapMap cell lines with European (Utah residents with northern and western European ancestry [CEU]; n = 90) or African (Yoruba people in Ibadan, Nigeria [YRI]; n = 90) ancestry. Results: We identified 44 genetic variants including eight coding SNPs in RRM1 and 15 SNPs including one coding SNP in RRM2. RRM1 and RRM2 mRNA expression levels were significantly correlated with each other in both CEU and YRI lymphoblast cell lines, and in leukemic blasts from acute myeloid leukemia (AML) patients (AML97, n = 89; AML02, n = 187). Additionally, RRM1 expression was higher among patient features indicative of a high relapse hazard. We evaluated SNPs within the RRM1 and RRM2 genes in the HapMap lymphoblast cell lines from CEU and YRI panels for association with expression and cytarabine chemosensitivity. SNPs of potential significance were further evaluated in AML patients. RRM1 SNPs rs1042919 (which occurs in linkage disequilbrium with multiple other SNPs) and promoter SNP rs1561876 were associated with intracellular 1-β-d-arabinofuranosyl-CTP levels, response after remission induction therapy, risk of relapse and overall survival in AML patients receiving cytarabine and cladribine. Conclusion: These results suggest that SNPs within ribonucleotide reductase might be helpful predictive markers of response to nucleoside analogs and should be further validated in larger cohorts. Original submitted 2 April 2013; Revision submitted 8 July 201.

UR - http://www.scopus.com/inward/record.url?scp=84883865174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883865174&partnerID=8YFLogxK

U2 - 10.2217/pgs.13.131

DO - 10.2217/pgs.13.131

M3 - Article

C2 - 24024897

AN - SCOPUS:84883865174

VL - 14

SP - 1449

EP - 1466

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 12

ER -